Traditional Chinese medicine composition for treating stress urinary incontinence
Through the decoction and treatment of the traditional Chinese medicine compositions of Astragalus, Codonopsis, Salvia miltiorrhizae, Raspberry, Citrus aurantium and Bupleurum, combined with the theory of spleen and kidney double supplementation, the treatment problem of stress urinary incontinence is solved, and significant clinical efficiency and safety are achieved improves urinary incontinence symptoms and quality of life.
Patent Information
- Application Number
- CN202411151537.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-21
AI Technical Summary
The prior art cannot effectively address stress urinary incontinence, a common and age-related disease, resulting in patients bearing their own financial burdens and high spending on society and healthcare systems.
Provide a traditional Chinese medicine composition, including raw Astragalus, Codonopsis pilosula, Salvia miltiorrhiza, Raspberry, Citrus aurantium and Bupleurum. Through the soaking and decoction steps during the decoction process, combined with the theory of spleen and kidney double supplementation, it is used to treat stress urinary incontinence. , enhance the body's immunity and improve pelvic floor muscle function.
Clinical randomized controlled studies showed that the total effective rate reached 89.86% after 4 weeks of treatment, which significantly improved the number of urinary incontinence and quality of life, and had no obvious toxic side effects. Animal experiments confirmed its inhibitory effect of regulatory hormones and apoptosis at the basal level. .
Smart Images

Figure CN118903281A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of stress urinary incontinence, and more particularly to a traditional Chinese medicine composition for treating stress urinary incontinence. Background Art
[0002] There are many epidemiological studies on female urinary incontinence. The results of different studies show that the prevalence of the disease varies greatly, which is related to the study population, measurement period and method used to assess severity. Studies have found that 23%-45% of the female population have varying degrees of urinary incontinence, of which about 50% are SUI. The prevalence of SUI in women in my country is about 18.9%, and the prevalence continues to increase with age. It can reach 28.2% at the age of 50-59, which is the peak age of SUI. The high incidence determines the high expenditure of the medical system on medical consultation and the supply of urinary incontinence materials. However, due to the low social acceptance of this disease, many patients bear the economic burden of urinary incontinence pads themselves. A meta-analysis in 2004 evaluated the socioeconomic burden of urinary incontinence. The cumulative annual expenditure in Canada, Germany, Italy, Spain, Sweden and the United Kingdom was about 7 billion euros, and the expenditure in the United States in 2007 was 66 billion euros. my country has entered an aging society. Urinary incontinence, an international and socialized disease that is positively correlated with age, is bound to cause more socioeconomic and hygiene problems. Despite the development of standardized recommendation guidelines in many countries, urinary incontinence remains uncured.
[0003] The theory of "spleen and kidney supplementation" is feasible for the treatment of SUI: SUI belongs to the category of "bladder cough", "enuresis", "incontinence" and other categories in traditional Chinese medicine. It is caused by spleen deficiency and inability to transport and transform, bladder malnutrition and dysfunction of opening and closing, or muscle malnutrition and inability to hold and control; kidney deficiency and inability to transform qi, bladder opening and closing are not favorable, resulting in incontinence. The spleen cannot transform without innate qi, and the kidney cannot produce without acquired qi, which ultimately leads to spleen and kidney deficiency. The treatment is "strengthening the spleen and strengthening the kidney, replenishing qi and activating blood circulation, reducing urine and stopping enuresis". In the formula, raw Astragalus and Codonopsis are both the main drugs for tonifying the middle and replenishing qi. Raw Astragalus is sweet and warm, enters the spleen and lung meridians, and is an important Qi-tonifying drug in traditional Chinese medicine. It has the effects of tonifying qi and strengthening the spleen, raising yang and lifting sunken, and healing sores and promoting tissue regeneration. Codonopsis is sweet, neutral in nature, and can strengthen the spleen and replenish qi, and is used together with raw Astragalus; raspberry is sweet and sour, neutral in nature, and can benefit the kidney, consolidate essence, and reduce urine as the auxiliary drugs; Salvia miltiorrhiza can promote blood circulation and remove blood stasis, Citrus aurantium can break up qi and guide stagnation, and Bupleurum can soothe the liver and promote qi. The three are used together as adjuvant drugs, which can make qi vigorous and blood circulate, and replenish qi without stagnation. The whole formula combines tonifying the spleen, benefiting the kidney, activating blood circulation, and promoting qi, taking into account both the symptoms and the root cause, and tonifying both the spleen and the kidney. Summary of the invention
[0004] In order to overcome the above defects of the prior art, the present invention provides a Chinese medicine composition for treating stress urinary incontinence to solve the problems existing in the above background technology.
[0005] The present invention provides the following technical scheme: a Chinese medicine composition for treating stress urinary incontinence, comprising the following ingredients: 15g of raw astragalus, 15g of codonopsis, 15g of salvia miltiorrhiza, 10g of raspberry, 10g of immature bitter orange, and 6g of bupleurum, wherein the raw astragalus and codonopsis are both the main drugs for invigorating the middle and replenishing qi, wherein the raw astragalus is sweet and warm, enters the spleen and lung meridians, is the main drug for invigorating qi in traditional Chinese medicine, has the effects of invigorating qi and strengthening spleen, raising yang and lifting sunken, astringing sores and promoting tissue regeneration, codonopsis is sweet in taste, neutral in nature, invigorates spleen and replenishes qi, and is used together with the raw astragalus; raspberry is sweet and sour in taste, neutral in nature, invigorates kidney, consolidates essence, and shrinks urine as the assistant; salvia miltiorrhiza activates blood circulation and removes blood stasis, immature bitter orange breaks qi and guides stagnation, and bupleurum soothes liver and promotes qi, and the three are used together as adjuvants, so as to make qi vigorous and blood flow, and invigorate qi without stagnation, and the whole prescription integrates invigorating spleen, invigorating kidney, invigorating blood circulation, and promoting qi, takes both the symptoms and the root cause into consideration, and invigorates spleen and kidney;
[0006] Current status of research on the medicinal flavor of Astragalus The main chemical components of Astragalus include flavonoids, saponins, polysaccharides, etc., which have the effects of improving immune function, anti-oxidation, protecting cardiovascular and cerebrovascular vessels, anti-tumor, promoting body metabolism, protecting the liver, and lowering blood sugar.
[0007] Current status of research on the medicinal flavor of Codonopsis pilosula The main chemical components of Codonopsis pilosula include acetylenes, alkaloids, triterpenes and saponins, phenylpropanoids, lignans, flavonoids, etc., which have the effects of enhancing immunity, protecting blood vessels, lowering blood sugar, protecting nerves, anti-oxidation, and anti-fatigue.
[0008] Current status of research on medicinal raspberry The main chemical components of raspberry include polysaccharides, flavonoids, phenols, terpenoids, alkaloids and organic acids, which have antioxidant, anti-aging, anti-inflammatory and anti-tumor effects. Studies have shown that raspberry can inhibit the expression of MMPs and inhibit collagen degradation.
[0009] Current status of research on the medicinal flavor of Salvia miltiorrhiza The main chemical components of Salvia miltiorrhiza include tanshinones, salvianolic acids, volatile oils, polysaccharides and nitrogen-containing compounds, which can dilate blood vessels, increase blood flow, improve blood hypercoagulability, and have anti-coagulant, anti-inflammatory, antioxidant, anti-fibrosis, anti-tumor, and organ protection effects.
[0010] Current status of research on the medicinal flavor of Bupleurum Root The main chemical components of Bupleurum Root include saposhnikosides, volatile oils, flavonoids and polysaccharides, which have pharmacological effects such as anti-depression, anti-inflammatory, immunomodulatory, and liver protection.
[0011] Current status of research on medicinal properties of stir-fried Citrus aurantium. Medical experts of all dynasties believed that stir-frying Citrus aurantium with bran could alleviate its harsh nature so as to avoid damaging the body's vital energy. The main chemical components of stir-fried Citrus aurantium with bran include flavonoids, alkaloids, volatile oils and other ingredients. The pharmacological effects of Citrus aurantium include regulating the gastrointestinal tract, anti-inflammatory, liver protection, and anti-ulcer.
[0012] Furthermore, the Chinese medicine composition needs to go through two steps of soaking and decocting during the decocting process.
[0013] Furthermore, the soaking step includes ① soaking the medicine first with cold water for thirty to fifty minutes; ② the amount of water added should be 7-12 times the weight of the medicinal piece, or the water should be added to soak the medicine surface 2-5 cm, or the amount of water added should be calculated based on the expected liquid volume, the amount of water absorbed by one decoction, and the loss of the medicinal liquid during one decoction; ③ the soaking liquid must not be lost after soaking, and it should be decocted together with the soaked medicine.
[0014] Further, the decoction step includes ① when decocting the first decoction, first heat it with high heat to reach boiling, then use low heat to slowly decoct, and keep it slightly boiling for a specified time (30-35 minutes). ② After the first decoction is completed, filter the liquid medicine with a filter cloth or a filter screen. If multiple doses of decoction are used, the liquid medicine should also be kept warm. ③ The amount of water added to the second decoction should be less than the amount of water added to the first decoction, or the amount of water added should be calculated based on the expected liquid volume, the water absorption of the second decoction, and the loss of the liquid medicine during the second decoction. First heat it with high heat to reach boiling, then use low heat to slowly decoct, and keep it slightly boiling for a specified time. Generally, the decoction time of the second decoction should be slightly shorter than that of the first decoction (20-25 minutes). ④ When decocting the medicine, stir it and prevent the liquid medicine from overflowing; control the decoction time and heat to prevent the occurrence of dry pot and burning of the medicine. ⑤ After the second decoction is completed, filter the liquid medicine with a filter cloth or a filter screen that meets food or medicinal requirements. For example, when multiple doses of decoction are required, the second decoction liquid is mixed with the first decoction liquid, and the mixed decoction liquid is boiled before packaging. The technical effects and advantages of the present invention are as follows:
[0015] 1. The present invention strictly follows the clinical randomized controlled and observational study design, and according to the "Guidelines for the Diagnosis and Treatment of Urinary Incontinence" (2022, "Guidelines for the Diagnosis and Treatment of Urological and Men's Diseases in China") and the internationally commonly used urinary incontinence outcome indicator judgment criteria, the test results show that at the end of 4 weeks of treatment, the results of 69 samples showed that the Qishizhiyi prescription combined with pelvic floor muscle training significantly improved the ICI-Q-SF score, the number of 24h urinary incontinence, and improved the I-QOL score. The total clinical effective rate reached 89.86%, and there were no obvious toxic and side effects.
[0016] 2. The present invention has shown through animal-based experimental studies that the Qishi Zhiyi prescription can significantly reduce collagen degradation, regulate hormone levels, reduce oxidative stress damage, and inhibit cell apoptosis, which confirms from a basic aspect that the Qishi Zhiyi prescription has the effect of regulating connective tissue factor and hormone levels and inhibiting cell apoptosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 Comparison of ALLP values among groups before and after intervention;
[0018] Figure 2 HE staining of levator ani muscle tissue of rats in each group (x40);
[0019] Figure 3Effect of Qishizhiyi prescription on the damage of vaginal anterior wall tissue in SUI rats (HE, 40×);
[0020] Figure 4 Effect of Qishizhiyi prescription on the damage of vaginal anterior wall tissue in SUI rats (Masson, 40×);
[0021] Figure 5 Effects of Qishizhiyi prescription on proliferation and apoptosis of anterior vaginal wall cells in SUI rats (TUNEL, 100
[0022] ×);
[0023] Figure 6 Serum ET-1 and NO concentrations of rats in each group after intervention;
[0024] Figure 7 Serum ROS and GSH-PX concentrations of rats in each group after intervention;
[0025] Figure 8 Serum E2 and T concentrations of rats in each group after intervention;
[0026] Fig. 9 Expression levels of related proteins in levator ani muscle tissue of rats in each group (x±s, n=4);
[0027] Fig.10 Expression levels of related proteins in the anterior vaginal wall of rats in each group (n=3). DETAILED DESCRIPTION
[0028] The technical scheme of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the present invention. In addition, the forms of the various structures described in the following embodiments are merely illustrative, and the Chinese medicine composition for treating stress urinary incontinence involved in the present invention is not limited to the various structures described in the following embodiments. All other embodiments obtained by ordinary technicians in this field without making creative work belong to the scope of protection of the present invention.
[0029] The invention provides a Chinese medicine composition for treating stress urinary incontinence, comprising the following ingredients: 15g of raw astragalus, 15g of codonopsis, 15g of salvia miltiorrhiza, 10g of raspberry, 10g of immature bitter orange, and 6g of bupleurum. In the formula, raw astragalus and codonopsis are both main drugs for invigorating the middle and replenishing qi. Raw astragalus is sweet and warm, enters the spleen and lung meridians, is an important qi-invigorating drug in traditional Chinese medicine, has the effects of invigorating qi and strengthening spleen, lifting yang and lifting sunken meridians, astringing sores and promoting tissue regeneration. Codonopsis is sweet in taste, neutral in nature, invigorates spleen and replenishes qi, and is used together with raw astragalus; raspberry is sweet and sour in taste, neutral in nature, invigorates kidney, consolidates essence, and shrinks urine as a subordinate; salvia miltiorrhiza activates blood circulation and removes blood stasis, immature bitter orange breaks qi and guides stagnation, and bupleurum soothes liver and promotes qi circulation. The three are used together as adjuvants to make qi vigorous and blood circulate, and invigorate qi without stagnation. The whole formula integrates invigorating spleen, invigorating kidney, invigorating blood circulation, and promoting qi circulation, takes both the symptoms and the root cause into consideration, and invigorates spleen and kidney.
[0030] Current status of research on the medicinal flavor of Astragalus The main chemical components of Astragalus include flavonoids, saponins, polysaccharides, etc., which have the effects of improving immune function, anti-oxidation, protecting cardiovascular and cerebrovascular vessels, anti-tumor, promoting body metabolism, protecting the liver, and lowering blood sugar.
[0031] Current status of research on the medicinal flavor of Codonopsis pilosula The main chemical components of Codonopsis pilosula include acetylenes, alkaloids, triterpenes and saponins, phenylpropanoids, lignans, flavonoids, etc., which have the effects of enhancing immunity, protecting blood vessels, lowering blood sugar, protecting nerves, anti-oxidation, and anti-fatigue.
[0032] Current status of research on medicinal raspberry The main chemical components of raspberry include polysaccharides, flavonoids, phenols, terpenoids, alkaloids and organic acids, which have antioxidant, anti-aging, anti-inflammatory and anti-tumor effects. Studies have shown that raspberry can inhibit the expression of MMPs and inhibit collagen degradation.
[0033] Current status of research on the medicinal flavor of Salvia miltiorrhiza The main chemical components of Salvia miltiorrhiza include tanshinones, salvianolic acids, volatile oils, polysaccharides and nitrogen-containing compounds, which can dilate blood vessels, increase blood flow, improve blood hypercoagulability, and have anti-coagulant, anti-inflammatory, antioxidant, anti-fibrosis, anti-tumor, and organ protection effects.
[0034] Current status of research on the medicinal flavor of Bupleurum Root The main chemical components of Bupleurum Root include saposhnikosides, volatile oils, flavonoids and polysaccharides, which have pharmacological effects such as anti-depression, anti-inflammatory, immunomodulatory, and liver protection.
[0035] Current status of research on medicinal properties of stir-fried Citrus aurantium. Medical experts of all dynasties believed that stir-frying Citrus aurantium with bran could alleviate its harsh nature so as to avoid damaging the body's vital energy. The main chemical components of stir-fried Citrus aurantium with bran include flavonoids, alkaloids, volatile oils and other ingredients. The pharmacological effects of Citrus aurantium include regulating the gastrointestinal tract, anti-inflammatory, liver protection, and anti-ulcer.
[0036] Furthermore, the Chinese medicine composition needs to go through two steps of soaking and decocting during the decocting process.
[0037] Furthermore, the soaking step includes ① soaking the medicine first with cold water for thirty to fifty minutes; ② the amount of water added should be 7-12 times the weight of the medicinal piece, or the water should be added to soak the medicine surface 2-5 cm, or the amount of water added should be calculated based on the expected liquid volume, the amount of water absorbed by one decoction, and the loss of the medicinal liquid during one decoction; ③ the soaking liquid must not be lost after soaking, and it should be decocted together with the soaked medicine.
[0038] Further, the decoction step includes ① when decocting the first decoction, first heat it with high heat to reach boiling, then use low heat to slowly decoct, and keep it slightly boiling for a specified time (30-35 minutes). ② After the first decoction is completed, filter the liquid medicine with a filter cloth or a filter screen. If multiple doses of decoction are used, the liquid medicine should also be kept warm. ③ The amount of water added to the second decoction should be less than the amount of water added to the first decoction, or the amount of water added should be calculated based on the expected liquid volume, the water absorption of the second decoction, and the loss of the liquid medicine during the second decoction. First heat it with high heat to reach boiling, then use low heat to slowly decoct, and keep it slightly boiling for a specified time. Generally, the decoction time of the second decoction should be slightly shorter than that of the first decoction (20-25 minutes). ④ When decocting the medicine, stir it and prevent the liquid medicine from overflowing; control the decoction time and heat to prevent the occurrence of dry pot and burning of the medicine. ⑤ After the second decoction is completed, filter the liquid medicine with a filter cloth or a filter screen that meets food or medicinal requirements. When decocting multiple doses of medicine, mix the second decoction liquid with the first decoction liquid, and make the mixed liquid boil before packaging.
[0039] Embodiment 1
[0040] A total of 69 female patients with mild to moderate stress urinary incontinence of spleen and kidney deficiency type diagnosed from January 2021 to December 2023 were selected.
[0041] Table 1 General information of patients
[0042]
[0043]
[0044] Inclusion criteria were:
[0045] (1) Western medicine diagnosis is based on the diagnostic criteria for stress urinary incontinence in the "Guidelines for Diagnosis and Treatment of Urological Diseases in China" (2022 edition);
[0046] (2) TCM syndrome differentiation and classification is based on the "Standards for Diagnosis and Efficacy of TCM Diseases and Syndromes" and the "Guidelines for Clinical Research of New Chinese Medicines" to formulate the syndrome differentiation standards for spleen and kidney deficiency: urinary incontinence, chills and cold limbs, sore waist and knees, poor appetite and abdominal distension, lower abdominal distension, loose stools, fatigue, loose stools, low back pain, tinnitus, pale tongue, and weak pulse.
[0047] (3) The clinical data were complete and there were no missing items;
[0048] (4) Patients with stress urinary incontinence have no contraindications to the drugs used in this study.
[0049] Exclusion criteria were:
[0050] (1) Patients with severe urinary tract infection and other types of urinary incontinence;
[0051] (2) Patients with severe urinary incontinence caused by urethral sphincter insufficiency, ectopic ureter, etc. who require surgical treatment;
[0052] (3) vaginal bleeding or inflammation;
[0053] (4) Patients with severe systemic diseases;
[0054] (5) Patients with mental illness or language disorders;
[0055] (6) Pregnancy;
[0056] (7) Those who are allergic to the drug;
[0057] (8) Patients without complete follow-up data before and after treatment or those who have not completed the treatment cycle.
[0058] The intervention measures are:
[0059] Qishi Zhiyi prescription combined with pelvic floor muscle training. Qishi Zhiyi prescription is composed of 15g raw astragalus, 15g Codonopsis pilosula, 15g Salvia miltiorrhiza, 10g Rubus idaeus, 10g Citrus aurantium, and 6g Bupleurum. Take one dose per day, decoct in water once in the morning and evening, take after meals, 100ml each time.
[0060] Treatment course: 4 weeks of treatment, and no other similar drugs are taken during the treatment period;
[0061] The observation indicators are:
[0062] ICI-Q-SF score
[0063] The ICI-Q-SF questionnaire survey was collected from patients before and after treatment, including the frequency of urine leakage, the amount of urine leakage and the degree of impact on quality of life. The total score is 21 points, with the lowest score being 0. According to the recommendations of the International Continence Association, the severity of urinary incontinence can be divided into three levels based on the questionnaire score: ≤7 points for mild; 8-13 points for moderate; 14-21 points for severe;
[0064] I-QOL score
[0065] The I-QOL scores of patients were collected before and after treatment, including the psychological impact, social barriers and behavioral restrictions caused by urinary incontinence on patients. There are 22 questions in total, each with 5 levels, and each level has a different score, ranging from 1 to 5 points. The lower the total score, the worse the quality of life of patients due to urinary incontinence.
[0066] Number of urinary incontinence in 24 hours
[0067] Compare the number of urinary incontinence in patients before and after treatment within 24 hours;
[0068] Efficacy criteria
[0069] Refer to China's "Guidelines for the Diagnosis and Treatment of SUI in Women (2017)", and judge the efficacy based on symptom improvement and objective monitoring items. ① Ineffective: There is no significant change in the patient's clinical symptoms of urinary incontinence and the frequency of urinary incontinence, and the urine pad test is positive; ② Effective: The patient's urine leakage frequency and symptoms are reduced compared with before treatment; ③ Significantly effective: The patient's urine leakage frequency is reduced, the symptoms are alleviated, and the number of urine pads used is significantly reduced; ④ Cured: The patient's urine leakage symptoms disappear, no urine pads are used, and no urine leakage occurs. Total effective rate = (cured cases + markedly effective cases + effective cases) / total cases × 100%;
[0070] Adverse Reactions
[0071] According to the CTCAE adverse reaction evaluation criteria, all adverse reactions and their severity during the patient's treatment were recorded.
[0072] The statistical methods are:
[0073] SPSS 21.0 statistical software was used to process the data. The baseline data of the patients were only analyzed descriptively. Continuous variables that met the normal distribution were expressed as mean ± standard deviation (xˉ±s), and those that did not meet the normal distribution were expressed as median and upper and lower quartiles [M(P25, P75)]; categorical variables were expressed as frequency and percentage. Paired sample t test was used for continuous variables that met the normal distribution, and Wilcoxon signed rank test was used for those that did not meet the normal distribution; McNemar test or McNemar-Bowker test was used for categorical variables. P < 0.05 indicated that the difference was statistically significant.
[0074] result
[0075] Efficacy analysis
[0076] After 4 weeks of treatment, the ICI-Q-SF score [5.30 (4.00, 7.00)] was significantly lower than that before treatment [9.21 (7.50, 11.00)], and the difference was statistically significant (P < 0.01); the I-QOL score (64.34±4.79) was higher than that before treatment (52.55±4.05), and the difference was statistically significant (P < 0.01); the number of 24-hour urinary incontinence [2.16 (1.00, 3.00)] was significantly reduced compared with that before treatment [4.30 (3.00, 5.00)] (P < 0.01).
[0077] Table 2 Comparison of scale scores and urinary incontinence frequency before and after treatment
[0078]
[0079] The total effective rate of clinical treatment reached 89.86%.
[0080] Table 3 Criteria for judging the efficacy after treatment
[0081]
[0082] Adverse Reactions
[0083] Only one patient developed mild diarrhea during treatment.
[0084] in conclusion
[0085] 1. Qishizhiyi prescription combined with pelvic floor muscle training can improve the ICI-Q-SF score of female SUI patients with mild to moderate spleen and kidney deficiency;
[0086] 2. Qishizhiyi prescription combined with pelvic floor muscle training can reduce the I-QOL score of female SUI patients with mild to moderate spleen and kidney deficiency;
[0087] 3. Qishizhiyi prescription combined with pelvic floor muscle training can reduce the frequency of 24-hour urinary incontinence in female SUI patients with mild to moderate spleen and kidney deficiency;
[0088] 4. Qishizhiyi prescription combined with pelvic floor muscle training can improve the clinical cure rate and total effective rate of female SUI patients with mild to moderate spleen and kidney deficiency type;
[0089] 5. The Qishizhiyi prescription combined with pelvic floor muscle training is safe for the treatment of mild to moderate female SUI patients with spleen and kidney deficiency.
[0090] Embodiment 2
[0091] Animal grouping and drug administration
[0092] After 1 week of adaptive feeding, 8 rats were randomly selected as blank controls (Control). The SUI rat model was prepared by the combined modeling method of "ovariectomy and castration + vaginal dilation", and urodynamics was used to detect whether the modeling was up to standard. Those who met the modeling standards were randomly divided into the model group (Model), the western medicine group (Midodrine), the Qishi Granule Optimized Formula Low-Dose Group (QSKL-L), and the Qishi Granule Optimized Formula High-Dose Group (QSKL-H), with 10 rats in each group.
[0093] The dosage was calculated according to the clinical dosage and the body surface coefficient of the animals. Methods: The dosage was calculated according to body weight. The blank group and the model group were gavaged with 0.1 ml·kg-1·d-1 of normal saline; the western medicine group was given 0.45 mg·kg-1·d-1 of midodrine hydrochloride solution; the low-dose group (equivalent dose) and high-dose group of the optimized Qishi Granule were given 6.39 g·kg-1·d-1 and 12.87 g·kg-1·d-1 of the optimized Qishi Granule, respectively. The intervention was carried out by gavage at a fixed time every day for 2 weeks.
[0094] Draw materials
[0095] After the last administration, urodynamics was tested first, then food and water were fasted for 12 hours, and the rats were weighed. After anesthesia, the abdominal cavity was opened along the midline of the abdomen, and a transverse incision was made on both sides at the bottom. Blood was collected from the abdominal aorta, and centrifuged at 4°C for 15 minutes at 3000rpm. After the serum was collected, it was first stored in a -20°C refrigerator, and then transferred to a -80°C refrigerator for the detection of sex hormones, etc. The pubic symphysis was cut with scissors, and the cut pubic symphysis was separated to both sides to fully expose the anterior vaginal wall, and the anterior vaginal wall was cut along the external opening of the vagina; the perineum on one side of the rat was separated, and the longitudinal muscle bundle running between the pubic symphysis and the coccyx was visible, which was the pubococcygeus muscle in the levator anus muscle. Gently fix with tweezers, cut 100 mg of pubococcygeus muscle specimen, rinse the specimen with saline, and fix it with formalin after rinsing; the pubococcygeus muscle on the other side was cut in the same way, the tissue was wrapped in tin foil, and quickly placed in liquid nitrogen for freezing, and stored in a -80°C refrigerator.
[0096] Detection indicators
[0097] HE staining of levator ani muscle and anterior vaginal wall tissue
[0098] The specimens were fixed in 4% paraformaldehyde solution for 24 hours; after the specimens were taken out, they were dehydrated with gradient ethanol; after being soaked in xylene for transparency; after being soaked in paraffin, they were embedded and sliced; after being dewaxed and hydrated, they were stained with hematoxylin and eosin, and then sealed; the pathological sections were subsequently scanned, and the pathological changes of the tissues were observed using SlideViewer software;
[0099] Masson staining of the anterior vaginal wall
[0100] After routine dewaxing and hydration, the anterior vaginal wall tissue sections were placed in Weigert iron hematoxylin staining solution for 8 minutes; differentiated in acidic ethanol differentiation solution for 10 seconds, washed with water; returned to blue in Masson blue solution for 5 minutes, washed with water; stained with Ponceau fuchsin staining solution for 10 minutes; washed with weak acid working solution (distilled water: weak acid solution = 2:1) for 1 minute. Washed with phosphomolybdic acid solution for 2 minutes; continued to wash with weak acid working solution for 1 minute; placed in aniline blue staining solution for 2 minutes. Washed with weak acid working solution for 1 minute; dehydrated with gradient ethanol, transparentized with xylene, sealed with neutral gum after drying, and observed the pathological changes of the anterior vaginal wall tissue under a microscope;
[0101] TUNEL staining of the anterior vaginal wall
[0102] The paraffin sections of the anterior vaginal wall were dewaxed in xylene and hydrated with gradient alcohol. 50 μL of reaction solution was added to the tissue and reacted at 37°C in the dark for 1 hour. Then 50 μL of Streptavidin-TRITC labeling solution was added and the reaction continued for 30 minutes. DAPI staining solution was used for 10 minutes, and the sections were washed with PBS buffer and sealed with anti-fluorescence quencher. The apoptosis of the anterior vaginal wall cells was observed under a fluorescence microscope.
[0103] Serum index detection
[0104] (1) Determination of vasoactive substance indicators: Endothelin-1 (ET-1): ET-1 level was determined by double antibody sandwich ELISA method strictly according to the kit instructions; nitric oxide (NO) content: NO level was determined by nitrate reductase method according to the kit instructions.
[0105] (2) Determination of oxidative stress indicators: Reactive oxygen species (ROS) detection: According to the instructions of the kit, the ROS level was determined by the chemiluminescence method; Glutathione peroxidase (GSH-PX) detection: According to the instructions of the kit, the GSH-PX level was determined by the colorimetric method.
[0106] (3) Serum hormone index determination: Testosterone (T) detection, estrogen (E2) detection: According to the kit instructions, enzyme-linked immunosorbent assay was used to determine T and E2 levels;
[0107] Western-blot was used to detect the expression of MMP-9, TIMP-1, and TGF-β1 proteins in the levator ani muscle tissue of rats, and the expression of pPI3K-P85, pAKT, BCL-2, and BAX proteins in the anterior vaginal wall tissue.
[0108] The levator ani muscle / anterior vaginal wall tissue in liquid nitrogen was taken out, lysed and centrifuged, and the anterior vaginal wall cells were collected to extract total protein. The protein was quantified by BCA method, and the sample buffer was added and denatured. According to the molecular weight of the target protein, the separation gel concentration was 12% and 8%, and the concentration gel concentration was 5%. Take 20ug protein, transfer to the membrane after gel electrophoresis, and immerse the membrane completely in 3% BSA-TBST and shake it gently at room temperature for 30min; after removing the blocking solution, dilute the primary antibody with 3% BSA-TBST and incubate it at 4℃ overnight. After incubation at room temperature for 30min on the second day, rinse with TBST 5 times, 3min / time. Dilute the secondary antibody with 5% skim milk powder-TBST, shake it gently at room temperature for 40min, and wash it with TBST 6 times, 3min / time. After ECL was added to the membrane, it reacted for 3-5min, the film was exposed, developed for 2min, and fixed. β-actin was used as an internal reference for correction. Scan the film and use ImageJ software to perform grayscale analysis on the scanned bands.
[0109] 2. Results
[0110] Qishizhiyi prescription can significantly increase the ALPP value of SUI model rats and improve the pathological morphology of levator ani muscles and anterior vaginal wall.
[0111] Comparison of ALLP values before and after intervention
[0112] Before intervention, the ALPP values of the model group, low-dose group, high-dose group, and western medicine group were lower than those of the blank group (P<0.01); there was no difference among the model group, low-dose group, high-dose group, and western medicine group (P>0.05).
[0113] After intervention, ALPP values in all groups increased; compared with the blank group, ALPP value in the model group increased (P<0.01); compared with the model group, ALPP values in the low-dose group and high-dose group increased (P<0.05, P<0.01); ALPP value in the western medicine group increased, and the difference was not statistically significant (P>0.05).
[0114] There was no significant change in the blank group before and after the intervention (P>0.05); compared with before the intervention, the ALPP value of the model group increased after the intervention (P<0.05); the ALPP values of the low-dose group, high-dose group, and western medicine group all increased (P<0.01). The results are shown in Table 1 and Figure 1 ;
[0115] Table 1 Comparison of ALLP values in rats in each group before and after intervention (cmH2O, )
[0116]
[0117] Note: Compared with the blank group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01 Note: Compared with the blank group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01; before and after comparison within the group, compared with before intervention, ▲ P<0.05, ▲▲ P<0.01
[0118] HE staining of rat levator ani muscle tissue
[0119] HE staining results showed that the muscle fibers of the levator ani muscle tissue of SD female rats in the blank group were arranged neatly, tightly, continuously and completely, with uniform cytoplasm coloring and uniform intercellular spaces. The muscle fibers of the levator ani muscle tissue of rats in the model group were disordered and broken, with reduced muscle cell content, uneven cytoplasm coloring and different intercellular spaces. After intervention, the muscle fibers of the levator ani muscle tissue of rats were arranged neatly and continuously compared with those in the model group, and the number of muscle fibers increased. Figure 2 Note: A: blank group; B: model group; C: western medicine group; D: low-dose group of Qishi Zhiyi prescription; E: high-dose group of Qishi Zhiyi prescription.
[0120] HE staining of rat vaginal anterior wall tissue
[0121] The smooth muscle bundles of the anterior vaginal wall of rats in the blank group were thick and woven; the smooth muscle bundles of the anterior vaginal wall of rats in the model group were small and randomly distributed, with thinner muscle bundles and wider interfascicular spaces. The pathological damage in the western medicine group, the low-dose Qishi Zhiyi Fang group, and the high-dose Qishi Zhiyi Fang group showed different degrees of relief, as shown by the restoration of normal structure of some smooth muscle cells and a decrease in the number of necrotic cells. Figure 3 Note: A blank group; B model group; C western medicine group; D low-dose group of Qishizhiyi prescription; E high-dose group of Qishizhiyi prescription.
[0122] Masson staining
[0123] The smooth muscle bundles of the anterior vaginal wall of rats in the blank control group were thick and woven, with rich and dense collagen content, and less broken and disordered collagen; the smooth muscle of the anterior vaginal wall of rats in the model group was small and disorderly distributed, with thinner muscle bundles and wider gaps between muscle bundles, broken muscle fibers, and reduced blood vessels and nerve tissue components. The pathological damage in the western medicine group, the low-dose Qishi Zhiyi Fang group, and the high-dose Qishi Zhiyi Fang group showed varying degrees of relief, as shown by the restoration of normal structure of some smooth muscle cells, thicker muscle bundles, and denser muscle fibers. Masson staining results are shown in Figure 4 Note: A blank group; B model group; C western medicine group; D low-dose group of Qishizhiyi prescription; E high-dose group of Qishizhiyi prescription.
[0124] TUNEL staining
[0125] Compared with the blank group, the number of TUNEL-positive cells in the SUI model group was significantly increased (P < 0.01); after intervention, compared with the model group, the number of TUNEL-positive cells in the western medicine group, the high-dose Qishi Zhiyi prescription group, and the low-dose Qishi Zhiyi prescription group was significantly reduced (P < 0.01). See Table 2 and Figure 5 Note: A blank group; B model group; C western medicine group; D low-dose group of Qishizhiyi prescription; E high-dose group of Qishizhiyi prescription.
[0126] Table 2 Comparison of apoptosis rate of anterior vaginal wall cells in each group of rats
[0127]
[0128]
[0129] Note: Compared with the blank group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01Effects of Qishizhiyi prescription on serum indexes of rats
[0130] Effect of Qishizhiyi Recipe on Active Substances in Vascular Endothelial Cells
[0131] Compared with the blank group, the serum ET-1 concentration of rats in the SUI model group was significantly increased, and the NO concentration was significantly decreased (P < 0.01); compared with the model group, the serum ET-1 concentration of rats in the low-dose group, high-dose group, and western medicine group was significantly decreased (P < 0.01); the serum NO concentration of rats in the high-dose group and western medicine group was significantly increased (P < 0.01); the results are shown in Tables 3 and Figure 6 Note: Compared with the blank group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01.
[0132] Table 3 Serum ET-1 and NO concentrations of rats in each group after intervention
[0133]
[0134] Note: Compared with the blank group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01Effect of Qishizhiyi prescription on oxidative stress
[0135] Compared with the blank group, the ROS concentration of rats in the SUI model group increased, and the GSH-PX concentration decreased (P < 0.01); after intervention, compared with the model group, the ROS concentration of the low-dose group, high-dose group, and western medicine group decreased (P < 0.01); the GSH-PX concentration increased (P < 0.01). The results are shown in Tables 4 and Figure 7 Note: Compared with the blank group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01.
[0136] Table 4 Serum ROS and GSH-PX concentrations of rats in each group after intervention
[0137]
[0138] Note: Compared with the blank group, *P<0.05, **P<0.01; compared with the model group, #P<0.05, ##P<0.01
[0139] Effect of Qishizhiyi Recipe on Serum Hormone Levels
[0140] Compared with the blank group, the E2 and T concentrations of rats in the SUI model group were decreased (P < 0.01); after intervention, compared with the model group, the E2 concentrations of the low-dose group, high-dose group, and western medicine group increased (P < 0.01); the T concentration of the high-dose group increased (P < 0.01). The results are shown in Tables 5 and Figure 8 Note: Compared with the blank group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01.
[0141] Table 5 Serum E2 and T concentrations of rats in each group after intervention
[0142]
[0143] Note: Compared with the blank group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01protein expression
[0144] Expression of MMP-9, TIMP-1, TGF-β1 and other proteins in levator ani muscle tissue
[0145] Compared with the blank group, the protein expressions of MMP-9, TIMP-1 and TGF-β1 in the SUI model group were significantly increased (P < 0.01). After intervention, compared with the model group, the protein expression of MMP-9 in the low-dose group and the high-dose group was significantly decreased (P < 0.01, P < 0.05). The protein expression of MMP-9 in the western medicine group was decreased, but there was no significant difference compared with the model group (P > 0.05). After intervention with western medicine and Qishizhiyifang, the protein expression of TIMP-1 was increased, and the difference was not statistically significant (P > 0.05). After intervention with western medicine and Qishizhiyifang, the protein expression of TGF-β1 was decreased, and the difference was not statistically significant (P > 0.05). The results are shown in Tables 6 and Fig. 9 Note: Compared with the blank group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01Table 6 Protein expression results of levator ani muscle tissue in rats in each group after intervention
[0146]
[0147] Note: Compared with the blank group, * P<0.05, **P<0.01; compared with the model group, # P<0.05, ## P<0.01 Effect of pPI3K-P85, pAKT, BCL-2 and BAX protein expression in anterior vaginal wall tissue
[0148] Compared with the blank group, the expression of p-PI3K and p-AKT proteins in SUI model rats was significantly decreased (P<0.01, P<0.05), the expression level of Bcl-2 protein was not statistically significant (P>0.05), and the expression of Bax protein was significantly increased (P<0.01). After intervention, compared with the model group, the expression of p-PI3K and p-AKT proteins in the anterior vaginal wall of rats in the high-dose group of Qishi Zhiyi Recipe was significantly increased (P<0.05, P<0.05), and there was no statistically significant difference in the other groups; there was no significant difference in the expression of Bcl-2 protein in the anterior vaginal wall of rats in each group (P>0.05); there was no significant difference in the expression of Bax protein in the anterior vaginal wall of rats in the western medicine group (P>0.05), and the expression of Bax protein in the high-dose and low-dose groups of Qishi Zhiyi Recipe was decreased (P<0.01, P<0.05); the results are shown in Fig.10 .
[0149] in conclusion
[0150] 1. Qishizhiyi prescription can significantly increase the ALPP value of SUI model rats, improve the pathological morphology of levator ani muscle and anterior vaginal wall, and reduce cell apoptosis.
[0151] 2. Qishizhiyi prescription can regulate the levels of serum TE-1, NO, ROS, GSH-PX, E2, T and other related indicators in SUI rats, indicating that Qishizhiyi prescription may exert its therapeutic effect by improving pelvic floor microcirculation, reducing oxidative stress damage, and regulating hormone levels.
[0152] 3. Qishizhiyi prescription may improve SUI by reducing the expression of MMP-9, reducing collagen degradation, and promoting TIMP / MMP balance.
[0153] 4. Qishizhiyi prescription may improve SUI by increasing the expression of PI3K and AKT proteins, reducing the expression of Bax protein, and inhibiting the apoptosis of anterior vaginal wall cells through the PI3K\AKT pathway.
[0154] Secondly: In the drawings of the embodiments disclosed in the present invention, only the structures related to the embodiments disclosed in the present invention are involved, and other structures can refer to the general design. In the absence of conflict, the same embodiment and different embodiments of the present invention can be combined with each other;
[0155] Finally: The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A Chinese medicine composition for treating stress urinary incontinence, characterized in that: It includes the following ingredients: 15g raw astragalus, 15g codonopsis, 15g salvia miltiorrhiza, 10g raspberry, 10g immature bitter orange, and 6g bupleurum. In the prescription, raw astragalus and codonopsis are the main medicines for tonifying the middle and replenishing qi. Among them, raw astragalus is sweet and warm, enters the spleen and lung meridians, and is an important qi-tonifying medicine in traditional Chinese medicine. It has the effects of tonifying qi and strengthening the spleen, raising yang and lifting sunken, astringing sores and promoting tissue regeneration. Codonopsis is sweet, neutral in nature, and can strengthen the spleen and replenish qi, and is used together with raw astragalus; raspberry is sweet and sour in nature, neutral in nature, and can benefit the kidney, consolidate essence, and reduce urine as the assistant; salvia miltiorrhiza promotes blood circulation and removes blood stasis, immature bitter orange breaks up qi and guides stagnation, and bupleurum soothes the liver and promotes qi. The three are used together as adjuvants, which can make qi prosperous and blood circulate, and tonify qi without stagnation. The whole prescription integrates tonifying the spleen, benefiting the kidney, promoting blood circulation, and promoting qi, taking into account both the symptoms and the root cause, and tonifying both the spleen and the kidney.
2. A Chinese medicine composition for treating stress urinary incontinence according to claim 1, characterized in that: The Chinese medicine composition needs to go through two steps of soaking and decocting during the decocting process.
3. A Chinese medicine composition for treating stress urinary incontinence according to claim 2, characterized in that: The soaking steps include: ① soaking the medicine in cold water for thirty to fifty minutes; ② the amount of water added should be 7-12 times the weight of the medicine, or water should be added to soak the medicine surface 2-5 cm, or the amount of water added can be calculated based on the expected liquid volume, the water absorption of one decoction and the loss of the medicine liquid during one decoction; ③ the soaking liquid must not be lost after soaking, and it should be decocted together with the soaked medicine.
4. A Chinese medicine composition for treating stress urinary incontinence according to claim 1, characterized in that: The decoction steps include: ① when decocting once, first heat with high heat to reach boiling, then switch to slow heat and keep it slightly boiling for a specified time (30-35 minutes); ② after the decoction is completed, filter the medicinal liquid with filter cloth or filter mesh. If multiple doses of medicine are to be decocted, the liquid medicine should also be kept warm. ③ The amount of water added to the second decoction should be less than that to the first decoction, or the amount of water added should be calculated based on the expected liquid volume, the amount of water absorbed by the second decoction, and the loss of liquid medicine during the second decoction; first heat with high heat to reach boiling, then switch to low heat to decoct slowly, and keep the slight boiling for the specified time. Generally, the decoction time of the second decoction should be slightly shorter than that of the first decoction (20-25 minutes); ④ When decocting medicine, stir it and prevent the liquid medicine from overflowing; control the decoction time and heat to prevent the occurrence of dry pot and burning of medicine; ⑤ After the second decoction is completed, filter the liquid medicine with filter cloth or filter mesh that meets food or medicinal requirements. If multiple doses of medicine are to be decocted, mix the liquid medicine of the second decoction with the liquid medicine of the first decoction, and make the mixed liquid medicine boil before packaging.
Citation Information
Patent Citations
Chinese medicinal preparation for treating deficiency of qi and blood, qi stagnation and blood stasis
CN102885925A
Traditional Chinese medicinal composition used for treating frequent urination and uroclepsia
CN106039183A
